K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · NBIX
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | NBIX | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC | $940K | Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit. Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage addition |
| 2026-04-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues |
| 2026-04-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2026-04-17 | NBIX | NEUROCRINE BIOSCIENCES INC. | LMH STRATEGIC SOLUTIONS | $30K | General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. |
| 2026-04-16 | NBIX | NEUROCRINE BIOSCIENCES INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare |
| 2026-01-20 | NBIX | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC | $900K | Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R |
| 2026-01-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues |
| 2026-01-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2026-01-18 | NBIX | NEUROCRINE BIOSCIENCES INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare |
| 2026-01-12 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2026-01-12 | NBIX | NEUROCRINE BIOSCIENCES INC. | LMH STRATEGIC SOLUTIONS | $30K | General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. |
| 2026-01-12 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $0 | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2025-10-20 | NBIX | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC | $900K | Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R&D) tax credit including the Ta |
| 2025-10-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2025-10-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-18 | NBIX | NEUROCRINE BIOSCIENCES INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare |
| 2025-10-15 | NBIX | NEUROCRINE BIOSCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues |
| 2025-07-21 | NBIX | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC | $890K | Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R&D) tax credit including the Ta |
| 2025-07-21 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2025-07-21 | NBIX | NEUROCRINE BIOSCIENCES INC. | LMH STRATEGIC SOLUTIONS | $10K | General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. |
| 2025-07-17 | NBIX | NEUROCRINE BIOSCIENCES INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare |
| 2025-07-16 | NBIX | NEUROCRINE BIOSCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues |
| 2025-07-15 | NBIX | NEUROCRINE BIOSCIENCES INC. | LMH STRATEGIC SOLUTIONS | $0 | General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. |
| 2025-04-21 | NBIX | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC | $910K | Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R&D) tax credit including the Ta |
| 2025-04-21 | NBIX | NEUROCRINE BIOSCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | IRA, prescription drug pricing, payment reform, innovation telehealth, mental health |
| 2025-04-21 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |
| 2025-04-17 | NBIX | NEUROCRINE BIOSCIENCES INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare |
| 2025-01-21 | NBIX | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC | $830K | Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act. Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. |
| 2025-01-21 | NBIX | NEUROCRINE BIOSCIENCES INC. | RICCHETTI INCORPORATED | $50K | Issues related to mental health care and telehealth policies S. 2678, Outbound Investment Transparency Act of 2023 Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related Medicare Part D reform and its impact on Low Income Subsidy (LIS) patients Issues related to pharmaceutical industry, generally |
| 2025-01-20 | NBIX | NEUROCRINE BIOSCIENCES INC. | BGR GOVERNMENT AFFAIRS | $60K | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy |